Organism: Homo sapiens
Gene: 38816_at
Selected probe(set): 202289_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38816_at (202289_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-4.5443325
Number of Samples:8 / 10

Experimental	Langerhans cell histiocytosis study 2 (unifocal)
	Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control	normal epidermal Langerhans cell sample
	Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Relative Expression (log2-ratio):-4.4461956
Number of Samples:2 / 10

Experimental	Langerhans cell histiocytosis study 2 (multifocal)
	Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control	normal epidermal Langerhans cell sample
	Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Relative Expression (log2-ratio):-4.173321
Number of Samples:2 / 10

Experimental	Langerhans cell histiocytosis study 2 (multisystem)
	Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control	normal epidermal Langerhans cell sample
	Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Relative Expression (log2-ratio):3.9015322
Number of Samples:2 / 9

Experimental	expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control	expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

Relative Expression (log2-ratio):-3.849103
Number of Samples:40 / 2

Experimental	melanoma study 34 (metastatic)
	Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control	melanoma study 34 (in situ)
	Tumor tissue from the skin of patients with melanoma in situ.

Relative Expression (log2-ratio):-3.7735815
Number of Samples:40 / 4

Experimental	melanoma study 34 (metastatic)
	Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control	normal skin tissue
	Normal skin tissue.

Relative Expression (log2-ratio):3.6583672
Number of Samples:6 / 2

Experimental	expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
	Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.
Control	expO ovary cancer study 1 (carcinoma, undifferentiated type, NOS; primary)
	Primary tumor tissue samples obtained from the ovary of patients with carcinoma, undifferentiated type (NOS).

Relative Expression (log2-ratio):3.5769396
Number of Samples:2 / 27

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):3.5491428
Number of Samples:2 / 13

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-3.4529123
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.